Scala Biodesign closed a $16 million Series A round in late March, with Grove Ventures leading and TLV Partners and Deep Insight joining—bringing the company's total haul, including an Israel Innovation Authority grant, to roughly $21.3 million. Not enormous by biotech standards, but notable timing: it arrives about three years after the Tel Aviv-based startup surfaced from stealth mode with a seed round in 2023.
What caught the eye of investors, perhaps more than the funding figure itself, was the customer roster. Scala now counts nine of the world's top 20 pharmaceutical companies as clients, up from five reported last spring. In an industry famously deliberate about adopting new computational tools—one where "Let's run another validation study" is practically a mantra—that kind of uptake suggests something is working.
The Promise: Skip the Iteration
Scala's core pitch revolves around speed. Its platform, ScalaOS, is designed to deliver dozens of beneficial protein mutations in a single computational pass—no endless cycles of lab testing, no months lost to iterative tweaking. The software blends atomistic physics, evolutionary data, and machine learning to redesign enzymes, antibodies, therapeutic proteins, and vaccine antigens. Company materials describe it as "no-code" and "self-serve," accessible enough that R&D teams without deep computational chops can operate it independently.
At Biotrans 2025, an enzyme engineering conference, Scala ran a hands-on workshop to demonstrate just that accessibility. The implicit message: you don't need a PhD in structural biology to use this thing.
Whether that democratization pitch holds up under real-world pressure remains to be seen. Computational protein design has long promised to revolutionize drug development, yet the graveyard of overhyped platforms is not small.
Real-World Traction, or At Least Early Wins
Still, Scala has posted results that go beyond vaporware. The company contributed design work to a malaria vaccine candidate now advancing through Phase II trials in West Africa, according to statements from CTO Dr. Adi Goldenzweig. The redesign reportedly enabled the vaccine to withstand ambient temperatures and be produced in bacterial systems—practical advantages for deployment in regions without reliable cold chains.
On the industrial enzyme side, a collaboration with Spanish energy giant Repsol yielded a sevenfold jump in cytochrome P450 activity, leaping from 4.5% to 32% conversion in one design round, per an October case study. Boehringer Ingelheim, meanwhile, used the platform to stabilize tricky drug targets and scale up production while preserving biological function, the company disclosed with the Series A.
These aren't just incremental gains. A sevenfold improvement in enzyme efficiency, delivered in weeks rather than quarters, is the kind of outcome that gets procurement teams to return emails.
Weizmann Roots, Commercial Ambitions
The founding trio—CEO Dr. Ravit Netzer, CTO Dr. Adi Goldenzweig, and Chief Scientist Prof. Sarel Fleishman—emerged from the Weizmann Institute of Science, where they developed PROSS, a widely cited computational method for protein stabilization. That academic pedigree opened doors early. Scala's client list now includes Boehringer Ingelheim, BASF, Teva, Repsol, and Intel, among others.
The company employs around 25 people in Tel Aviv. Series A proceeds will fund further platform development, though Scala has been circumspect about specifics—no grand pronouncements about headcount doubling or aggressive U.S. expansion. The focus, at least in public messaging, remains on refining ScalaOS and proving out its one-cycle design thesis across more use cases.
A Crowded, Suddenly Hot Market
Scala is hardly alone in chasing the AI protein design opportunity. Generate Biomedicines went public in February with a $400 million IPO. Cradle pulled in a $73 million Series B in late 2024. Profluent raised $106 million around the same period. Market sizing estimates—always a bit squishy in emerging sectors—peg the AI protein design space at somewhere near $700 million currently, with projections climbing toward $2 billion within a few years.
That kind of capital influx tends to sharpen competitive dynamics. It also raises the bar for what counts as differentiation. Scala's angle—rapid, non-iterative design accessible to non-specialists—is compelling in theory. But theory and therapeutic approval timelines don't always align neatly.
For now, the nine pharma partnerships offer a tangible vote of confidence. Whether ScalaOS can scale from enzyme optimization and vaccine tweaks to the far gnarlier challenges of novel drug discovery—where stakes, complexity, and regulatory scrutiny multiply—will determine if Scala remains a useful tool or becomes a foundational platform.
The next year or two should clarify which trajectory is likelier.
